GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gain Therapeutics Inc (NAS:GANX) » Definitions » 3-Year ROIIC %

GANX (Gain Therapeutics) 3-Year ROIIC % : -1,403.52% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Gain Therapeutics 3-Year ROIIC %?

3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year. Gain Therapeutics's 3-Year ROIIC % for the quarter that ended in Dec. 2023 was -1,403.52%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Gain Therapeutics's 3-Year ROIIC % or its related term are showing as below:

GANX's 3-Year ROIIC % is ranked worse than
94.7% of 1358 companies
in the Biotechnology industry
Industry Median: -13.43 vs GANX: -1403.52

Gain Therapeutics 3-Year ROIIC % Historical Data

The historical data trend for Gain Therapeutics's 3-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gain Therapeutics 3-Year ROIIC % Chart

Gain Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
3-Year ROIIC %
Get a 7-Day Free Trial - - - -562.62 -1,403.52

Gain Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
3-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -1,403.52 - - -

Competitive Comparison of Gain Therapeutics's 3-Year ROIIC %

For the Biotechnology subindustry, Gain Therapeutics's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gain Therapeutics's 3-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gain Therapeutics's 3-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Gain Therapeutics's 3-Year ROIIC % falls into.



Gain Therapeutics 3-Year ROIIC % Calculation

Gain Therapeutics's 3-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:

3-Year ROIIC %=3-Year Incremental Net Operating Profit After Taxes (NOPAT)**/3-Year Incremental Invested Capital**
=( -22.3331108 (Dec. 2023) - -3.4838706 (Dec. 2020) )/( 2.35 (Dec. 2023) - 1.007 (Dec. 2020) )
=-18.8492402/1.343
=-1,403.52%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Gain Therapeutics  (NAS:GANX) 3-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Gain Therapeutics 3-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Gain Therapeutics's 3-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Gain Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
4800 Montgomery Lane, Suite 220, Bethesda, MD, USA, 20814
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.
Executives
Khalid Islam director C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Eric I Richman director C/O REV CAPITAL II, LLC, 9740 SORREL AVE, POTOMAC MD 20854
Jeffrey Scott Riley director C/O ADEONA PHARMACEUTICALS, INC, 3930 VARSITY DRIVE, ANN ARBOR MI 48108
Matthias Alder officer: Chief Operating Officer C/O MICROMET, INC., 6707 DEMOCRACY BLVD., STE. 505, BETHESDA MD 28017
Charles Evan Ballantyne officer: Chief Financial Officer 27 HEARTHSTONE ROAD, HOPKINTON MA 01748
Gianluca Fuggetta officer: Principal Accounting Officer C/O GAIN THERAPEUTICS, INC., 4800 MONTGOMERY LANE, SUITE 220, BETHESDA MD 20814
Salvatore Calabrese officer: Chief Financial Officer C/O GAIN THERAPEUTICS, INC., 4800 HAMPDEN LANE, SUITE 200, BETHESDA MD 20814
Hans Peter Hasler director C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
Gwen A Melincoff director C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Goldstein Dov A Md director
Claude Nicaise director 215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142
Manolo Bellotto officer: President and General Manager C/O GAIN THERAPEUTICS, INC., 4800 HAMPDEN LANE, SUITE 200, BETHESDA MD 20814